Molecular biomarkers of diffuse axonal injury: recent advances and future perspectives.

IF 3.9 3区医学 Q1 PATHOLOGY Expert Review of Molecular Diagnostics Pub Date : 2024-01-01 Epub Date: 2024-01-11 DOI:10.1080/14737159.2024.2303319

Youyou Zhang, Zhaoyang Li, Hui Wang, Zhiyong Pei, Shuquan Zhao

{"title":"Molecular biomarkers of diffuse axonal injury: recent advances and future perspectives.","authors":"Youyou Zhang, Zhaoyang Li, Hui Wang, Zhiyong Pei, Shuquan Zhao","doi":"10.1080/14737159.2024.2303319","DOIUrl":null,"url":null,"abstract":"Introduction: Diffuse axonal injury (DAI), with high mortality and morbidity both in children and adults, is one of the most severe pathological consequences of traumatic brain injury. Currently, clinical diagnosis, disease assessment, disability identification, and postmortem diagnosis of DAI is mainly limited by the absent of specific molecular biomarkers.Areas covered: In this review, we first introduce the pathophysiology of DAI, summarized the reported biomarkers in previous animal and human studies, and then the molecular biomarkers such as β-Amyloid precursor protein, neurofilaments, S-100β, myelin basic protein, tau protein, neuron-specific enolase, Peripherin and Hemopexin for DAI diagnosis is summarized. Finally, we put forward valuable views on the future research direction of diagnostic biomarkers of DAI.Expert opinion: In recent years, the advanced technology has ultimately changed the research of DAI, and the numbers of potential molecular biomarkers was introduced in related studies. We summarized the latest updated information in such studies to provide references for future research and explore the potential pathophysiological mechanism on diffuse axonal injury.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"39-47"},"PeriodicalIF":3.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2024.2303319","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Diffuse axonal injury (DAI), with high mortality and morbidity both in children and adults, is one of the most severe pathological consequences of traumatic brain injury. Currently, clinical diagnosis, disease assessment, disability identification, and postmortem diagnosis of DAI is mainly limited by the absent of specific molecular biomarkers.

Areas covered: In this review, we first introduce the pathophysiology of DAI, summarized the reported biomarkers in previous animal and human studies, and then the molecular biomarkers such as β-Amyloid precursor protein, neurofilaments, S-100β, myelin basic protein, tau protein, neuron-specific enolase, Peripherin and Hemopexin for DAI diagnosis is summarized. Finally, we put forward valuable views on the future research direction of diagnostic biomarkers of DAI.

Expert opinion: In recent years, the advanced technology has ultimately changed the research of DAI, and the numbers of potential molecular biomarkers was introduced in related studies. We summarized the latest updated information in such studies to provide references for future research and explore the potential pathophysiological mechanism on diffuse axonal injury.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

弥漫性轴突损伤的分子生物标志物：最新进展与未来展望。

导言：弥漫性轴索损伤（DAI）是创伤性脑损伤最严重的病理后果之一，在儿童和成人中的死亡率和发病率都很高。目前，DAI 的临床诊断、疾病评估、残疾鉴定和尸检诊断主要受限于缺乏特异性分子生物标志物：在这篇综述中，我们首先介绍了 DAI 的病理生理学，总结了以往动物和人体研究中报道的生物标志物，然后总结了用于 DAI 诊断的分子生物标志物，如β-淀粉样前体蛋白、神经丝、S-100β、髓鞘碱性蛋白、tau 蛋白、神经元特异性烯醇化酶、Peripherin 和 Hemopexin。最后，我们对未来 DAI 诊断生物标志物的研究方向提出了宝贵的意见：近年来，先进的技术最终改变了对 DAI 的研究，相关研究中引入了大量潜在的分子生物标志物。我们总结了这些研究的最新进展，为今后的研究提供参考，并探讨弥漫性轴索损伤的潜在病理生理机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Molecular Diagnostics 医学-病理学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy. Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.